Literature DB >> 3259880

Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver.

G Fabre1, P Crevat-Pisano, S Dragna, J Covo, Y Barra, J P Cano.   

Abstract

This report characterizes the cytochrome P-450 isozyme involved in midazolam metabolism. This study was undertaken into liver microsomal fractions prepared from untreated rabbits or animals treated with drugs known to specifically induce various cytochrome P-450 isozymes such as form LM2 by phenobarbital, LM4 and LM6 by 3-methylcholanthrene and beta-naphthoflavone, LM3a by ethyl alcohol and acetone, and LM3c by macrolide antibiotics (rifampicin, erythromycin and triacetyloleandomycin). Among this library of characterized microsomal preparations, only those obtained from macrolide antibiotic-treated rabbits exhibited a Type I binding spectrum upon addition of midazolam (Ks = 3.2-5.3 micrograms/ml; 10.6-17.5 microM) and significantly metabolized midazolam to its various hydroxylated metabolites (Km = 2.52 +/- 0.22 micrograms/ml; 8.32 +/- 0.73 microM and Vmax = 20 micrograms metabolites formed/min/mg proteins; 66 nmoles metabolites formed/min/mg proteins). The following observations further confirmed the specific involvement of the cytochrome P-450 LM3c isozyme: (i) only anti-cytochrome P-450 LM3c isozyme antibodies intensively inhibited midazolam metabolism, (ii) incubation of microsomes, prepared from TAO-treated rabbits, with midazolam in the presence of potassium ferricyanide which restored the functional cytochrome P-450 LM3c isozyme, increased midazolam metabolism to a similar extent, and (iii) in the presence of Cyclosporin A, a specific substrate of the rabbit cytochrome P-450 LM3c isozyme, midazolam metabolism was inhibited in a concentration-dependent manner. These data demonstrated that the rabbit cytochrome P-450 LM3c isozyme was predominantly involved in midazolam metabolism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259880     DOI: 10.1016/0006-2952(88)90541-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

Review 1.  Heat exposure and drugs. A review of the effects of hyperthermia on pharmacokinetics.

Authors:  J Vanakoski; T Seppälä
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

2.  Is cyclosporin A an inhibitor of drug metabolism?

Authors:  G Li; G Treiber; J Meinshausen; J Wolf; J Werringloer; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

Review 3.  Human hepatocytes as a key in vitro model to improve preclinical drug development.

Authors:  G Fabre; J Combalbert; Y Berger; J P Cano
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

4.  The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.

Authors:  C Ged; J M Rouillon; L Pichard; J Combalbert; N Bressot; P Bories; H Michel; P Beaune; P Maurel
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

5.  Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes.

Authors:  C R Barnett; G G Gibson; C R Wolf; P R Flatt; C Ioannides
Journal:  Biochem J       Date:  1990-06-15       Impact factor: 3.857

6.  Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta.

Authors:  J D Schuetz; S Kauma; P S Guzelian
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

7.  Azithromycin does not alter the effects of oral midazolam on human performance.

Authors:  M J Mattila; J Vanakoski; J J Idänpään-Heikkilä
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Delta 2-valproate biotransformation using human liver microsomal fractions.

Authors:  G Fabre; C Briot; E Marti; J P Montseny; M Bourrié; D Massé; Y Berger; J P Cano
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

9.  Insulin-mimetic effects of vanadate in preventing the increase of P450IIIA and P450IA subfamily proteins in streptozotocin-diabetic rats.

Authors:  A Verrecchia; A Guaitani
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

10.  In vitro forecasting of drugs which may interfere with the biotransformation of midazolam.

Authors:  M P Gascon; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.